GILD.NASDAQGilead Sciences, INC
13F-HR: Gilead Sciences 13F Holdings — June 30, 2026
Institutional Holdings Report (13F)
Gilead Sciences, Inc. reported 5 holdings worth $1.6B for the period ended June 30, 2026.
Summary
- Gilead Sciences, Inc. reported 5 holdings worth $1.6B as of June 30, 2026.
- Arcus Biosciences Inc. — $968.8M (58.76%), 31,424,760 SH.
- Lakefront Biotherapeutics — $500.2M (30.34%), 16,707,477 SH.
- Assembly Biosciences Inc. — $136.8M (8.3%), 4,977,089 SH.
- Kyverna Therapeutics Inc. — $36.8M (2.23%), 4,126,119 SH.
- Xilio Therapeutics Inc. — $6.2M (0.38%), 650,389 SH.
Top Holdings
Gilead Sciences, Inc. · 5 positions · $1.6B total · as of June 30, 2026
| Issuer | Value | % Port. | Shares |
|---|---|---|---|
| Arcus Biosciences Inc. | $968.8M | 58.76% | 31,424,760 |
| Lakefront Biotherapeutics | $500.2M | 30.34% | 16,707,477 |
| Assembly Biosciences Inc. | $136.8M | 8.3% | 4,977,089 |
| Kyverna Therapeutics Inc. | $36.8M | 2.23% | 4,126,119 |
| Xilio Therapeutics Inc. | $6.2M | 0.38% | 650,389 |
Keywords
13F, institutional holdings, Gilead Sciences, Inc., Arcus Biosciences Inc., Lakefront Biotherapeutics, Assembly Biosciences Inc., Kyverna Therapeutics Inc., Xilio Therapeutics Inc.
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.